Work

Pulmonary artery intimal sarcoma misdiagnosed as pulmonary embolism: MDM2 amplification as the diagnostic anchor in an unresectable tumor—a case report

Year: 2026
Type: preprint
Study design: Case Report
Abstract: Background Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive vascular malignancy whose clinical and radiological features overlap with those of pulmonary thromboembolism (PTE); most patients are initially anticoagulated, and no standard systemic therapy exists for unresectable disease. Amplification of MDM2 is the defining genomic event, yet it is usually treated as a supplementary finding rather than as a diagnostic test. Case presentation A 51-year-old man without thromboembolic risk factors presented with cough, sputum production, and chest discomfort. Contrast-enhanced computed tomography (CT) showed filling defects extending from the main pulmonary artery into both branches together with a 5.0 × 2.7 cm left upper lobe mass, and he received rivaroxaban until hemoptysis occurred. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT showed concordant hypermetabolism of the intravascular and parenchymal lesions. Two biopsies, including an expert review, narrowed the differential only to intimal sarcoma versus sarcomatoid carcinoma; next-generation sequencing then identified MDM2 amplification with CDKN2A deletion, a low tumor mutational burden (1.95 mutations/Mb), and negative PD-L1 expression, establishing MDM2-driven PAIS. Because the tumor was unresectable, he received six cycles of sintilimab, docetaxel, and cisplatin, two further cycles of sintilimab and docetaxel, consolidative intensity-modulated radiotherapy (60 Gy in 25 fractions), and maintenance sintilimab monotherapy. The best response was stable disease with a 27.9% reduction in the sum of target-lesion diameters, and progression-free survival reached 12.1 months without grade ≥3 immune-related adverse events. Conclusions When morphology and immunohistochemistry are indeterminate, MDM2 amplification can be the decisive diagnostic test rather than a supplementary finding, and it should be sought before empirical treatment is committed. Chemotherapy-primed PD-1 blockade followed by consolidative radiotherapy produced durable disease control in an immunologically cold tumor; prospective registries are needed to test this sequence.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7225878300
Cites:
Cited by:
Related to: 10